Inhibrx to Present Clinical Update on Ozekibart in Late-Line Colorectal Cancer
Key Insights
Inhibrx Biosciences will host a webcast on April 21, 2026, to provide clinical updates on ozekibart (INBRX-109) in combination with FOLFIRI (search) for late-line colorectal cancer (search) patients.
Ozekibart is a precision-engineered tetravalent death receptor 5 (search) (DR5 (search)) agonist antibody that has already demonstrated breakthrough efficacy in chondrosarcoma (search) trials.
The company's ChonDRAgon study showed ozekibart achieved a 52% reduction in disease progression risk and more than doubled median progression-free survival compared to placebo.
Inhibrx Biosciences announced it will host a live webcast presentation on April 21, 2026, at 1:30 p.m. Pacific Time to provide clinical updates from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI (search) in patients with locally advanced or metastatic, unresectable colorectal cancer (search).
Breakthrough Results in Chondrosarcoma Drive Expanded Development
Ozekibart has already demonstrated significant clinical success in chondrosarcoma (search), a rare bone cancer with limited treatment options. In October 2025, Inhibrx announced that its ChonDRAgon study met its primary endpoint, showing statistically significant and clinically meaningful median progression-free survival (PFS) for patients with advanced or metastatic chondrosarcoma.
The results were particularly compelling: ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, with a stratified hazard ratio of 0.479 (95% CI: 0.33, 0.68; P<0.0001). The treatment more than doubled median PFS to 5.52 months versus 2.66 months for placebo.
"Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma (search), a disease with no approved systemic options," the company stated.
Mechanism of Action and Regulatory Recognition
Ozekibart is a precision-engineered, tetravalent death receptor 5 (search) (DR5 (search)) agonist antibody designed to exploit tumor-biased cell death induced by DR5 activation. The FDA has recognized the therapeutic potential of this approach, granting Fast Track designation in January 2021 for metastatic or unresectable conventional chondrosarcoma (search) and orphan drug designation in November 2021.
The registrational ChonDRAgon trial, initiated in June 2021, was a randomized, blinded, placebo-controlled study that enrolled 206 patients across 67 sites worldwide, demonstrating the global interest in this novel therapeutic approach.
Expanding Clinical Applications
Beyond chondrosarcoma (search), Inhibrx is investigating ozekibart's potential across multiple tumor types in Phase 1/2 trials. The upcoming webcast will focus specifically on the colorectal cancer (search) combination study with FOLFIRI (search), a standard chemotherapy regimen. The company is also evaluating ozekibart in Ewing sarcoma (search) in combination with irinotecan/temozolomide.
Company Background and Pipeline
Inhibrx Biosciences, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, utilizes diverse protein engineering methods to address complex target and disease biology. The company was incorporated in January 2024 as a subsidiary of Inhibrx, Inc., following corporate restructuring that included the sale of the INBRX-101 program to Sanofi.
The current clinical pipeline includes ozekibart and INBRX-106, both utilizing multivalent formats where precise valency can be optimized in a target-centric manner to mediate appropriate agonist function.
Investors can access the webcast through the company's website, with the presentation remaining available for 60 days following the event. The company will also update its corporate presentation in the investor section of its website following the webcast.